SION (Sionna Therapeutics) Ending Cash Position: $64.29 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SION Sionna Therapeutics Inc SION
12 GF Score
Price $46.84
! 3 Warning Signs
View Full Analysis

What is Sionna Therapeutics Ending Cash Position?

Sionna Therapeutics SION +5.59% 12 Ending Cash Position is $64.29 Mil as of Mar. 2026. GuruFocus rates SION with a GF Score™ of 12/100. The stock has 3 warning signs investors should review.

Sionna Therapeutics's Ending Cash Position for the quarter that ended in Mar. 2026 was $64.29 Mil.

Sionna Therapeutics's quarterly Ending Cash Position increased from Sep. 2025 ($51.79 Mil) to Dec. 2025 ($59.41 Mil) and increased from Dec. 2025 ($59.41 Mil) to Mar. 2026 ($64.29 Mil).

Sionna Therapeutics's annual Ending Cash Position declined from Dec. 2023 ($39.48 Mil) to Dec. 2024 ($38.75 Mil) but then increased from Dec. 2024 ($38.75 Mil) to Dec. 2025 ($59.41 Mil).

Sionna Therapeutics Ending Cash Position Related Terms

Sionna Therapeutics Ending Cash Position Historical Data

* Premium members only.

The historical data trend for Sionna Therapeutics's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sionna Therapeutics Ending Cash Position Chart

Sionna Therapeutics Annual Data
Trend Dec22 Dec23 Dec24 Dec25
Ending Cash Position
55.80 39.48 38.75 59.41

Sionna Therapeutics Quarterly Data
Dec22 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only 83.66 41.95 51.79 59.41 64.29
SION
12GF Score
Sionna Therapeutics Inc SION
Ending Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sionna Therapeutics Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Sionna Therapeutics's Ending Cash Position for the fiscal year that ended in Dec. 2025 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=38.75+20.664
=59.41

Sionna Therapeutics's Ending Cash Position for the quarter that ended in Mar. 2026 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=59.414+4.873
=64.29

Frequently Asked Questions Learn more about Ending Cash Position →
What does a Ending Cash Position of $64.29 Mil mean?
Sionna Therapeutics (SION) has a Ending Cash Position of $64.29 Mil as of Mar. 2026. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Sionna Therapeutics and its competitors.
Is Sionna Therapeutics' Ending Cash Position too high?
Sionna Therapeutics' current Ending Cash Position is $64.29 Mil. Overall, Sionna Therapeutics has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Sionna Therapeutics' Ending Cash Position compare to TYRA and RAPP?
Sionna Therapeutics' Ending Cash Position of $64.29 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Biotechnology company?
A good Ending Cash Position depends on the Biotechnology industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Sionna Therapeutics and its competitors. Sionna Therapeutics's current Ending Cash Position is $64.29 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sionna Therapeutics stock overvalued right now?
Sionna Therapeutics (SION) has a current Ending Cash Position of $64.29 Mil. The current Ending Cash Position is $64.29 Mil. Sionna Therapeutics' overall GF Score™ is 12/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For Sionna Therapeutics (SION), the current Ending Cash Position is $64.29 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Sionna Therapeutics Business Description

Address 21 Hickory Drive, Suite 500, Waltham, MA, USA, 02451
Sionna Therapeutics Inc is a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF) patients by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein to deliver clinically meaningful benefits to CF patients. CF is a progressive and life-threatening genetic disease caused by inherited mutations in the CFTR gene, which heads to insufficient CFTR function. The Company is managed as one operating segment focused on the research and development of cystic fibrosis therapies.
12GF Score

Get the complete analysis for SION

Ending Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$46.84
Price